Dementia and Alzheimer Disease

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Michael H. Barnett, MBBS, PhD, FRACP; Nancy R. Foldvary-Schaefer, DO, FAAN; Sean J. Pittock, MD; Katherine W. Turk, MD; Erika U. Augustine, MD, MS; Jeffrey M. Statland, MD; and Chian-Chun Chiang, MD. [LISTEN TIME: 41 minutes]

Designed for self-directed use in a patient’s home or a healthcare facility, the Cumulus EEG device has potential to change the clinical trial landscape, allowing researchers to conduct more remote studies.

For those with an intermediate level of tau and clinical symptoms of Alzheimer disease, treatment with donanemab resulted in a 39% lower risk of progressing to the next stage of disease relative to placebo.

The neurologist at Montefiore Medical Center, Albert Einstein College of Medicine, discussed his experience in establishing a neurology department committee on diversity, equity, and inclusion. [WATCH TIME: 5 minutes]

The chief scientific officer at Alzheon discussed new, positive 12-month findings on ALZ-801, an investigational agent in development for patients with early-stage Alzheimer disease.

A group of experts in the care of patients with neurological conditions—Ali Jannati, MD, PhD; Madhav R. Thambisetty, MD, PhD; Daniel Ontaneda, MD, PhD; Peter J. Goadsby, MD, PhD, DSc; Andrew Russman, DO—shared their perspectives on hot topics of treatment and management in neurology from the 2023 American Academy of Neurology Annual Meeting.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute provided perspective on the in-depth testing neurologically healthy patients in the Brain Study will undergo. [WATCH TIME: 3 minutes]

The manager of Clinical Development-Research at Linus Health discussed potential avenues of research for the DCTclock and expanding its capabilities as a potential detector of cognitive decline. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Neurology.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 28, 2023.

The president elect of the Association of University Professors of Neurology discussed the benefits of working in neurology and the ways to not only attract new clinicians, but keep those already in the field. [WATCH TIME: 3 minutes]

The director of Cleveland Clinic's Epilepsy Center at the Cleveland Clinic Neurological Institute shared his insight into the findings of the World Brain Study, 15 months after its initiation.

The professor of neurology at Boston University Chobanian & Avedisian School of Medicine talked about diagnostic tools and using memory aids for patients with cognitive impairment at the 2023 AAN Annual Meeting. [WATCH TIME: 7 minutes]

The chief medical officer and cofounder of CND Life Sciences, who served as principal investigator of the study, offered insight into the Syn-ONe Test's clinical utility.

CND Life Sciences’ α-synuclein skin biopsy test showed sensitivity rates ranging from 92.7% to 100% across a number of assessed and clinically confirmed synucleinopathies, including Parkinson disease and dementia with Lewy bodies, among others.

The director of Cleveland Clinic’s Epilepsy Center provided an update on the World Brain Study, a large-scale, longitudinal study aimed to observe the early, underlying changes in neurological disorders. [WATCH TIME: 9 minutes]

The president elect of the Association of University Professors of Neurology provided thoughts on the promising concepts in neurology and the reasons young medical professionals should join the field.

The behavioral neurologist at VA Boston Healthcare System talked about screening patients for mild cognitive impairment to improve diagnosis in Alzheimer disease at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

The manager of Clinical Development-Research at Linus Health provided perspective on 2 analyses presented at the 2023 AAN Annual Meeting on the reliability of the DCTclock to detect cognitive impairment. [WATCH TIME: 4 minutes]

The senior investigator at the National Institute on Aging talked about targeting pathologies in neurodegenerative diseases at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine spoke about preserving brain function through medical, sociopolitical, and educational efforts as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Neurology.

Treatment with ALZ-801, an investigational agent in development for Alzheimer disease, resulted in more than 40% reduction in plasma p-tau181 at the end of the 12-month analysis.

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about the importance of vascular health in preventing cognitive impairment as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]

Neurology News Network for the week ending April 22, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 21, 2023.

Greater cumulative exposure to HbA1c concentrations in the range of 6% to less than 8%, targets proposed by most geriatrics’ guidelines for healthier older people, were associated with lower hazard of dementia.

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about brain health in relation to vascular health ahead of the 2023 AAN annual meeting. [WATCH TIME: 3 minutes]